Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call Transcript

Laura Sorel: This is Laura Sorel on for Jim Molloy. So regarding the agreement with Jaeb Center study of ILUVIEN in radiation retinopathy as mentioned, with the initiation expected to commence next year, when do you expect an overall interim look to be announced for this trial in particular? And then also for the NEW DAY study, what is the overall time line for this trial following expectations to complete enrollment early next year? And when might top line data be reported?

Rick Eiswirth: Yes. So for the DRCR study, I think from a confidentiality standpoint, we need to let them speak publicly about their time lines. But it is anticipated they’ll start next year. It’s a 600-patient study, so it will take a while to enroll. And it’s most likely going to take two years to enroll that study. So, the data will — it will be quite some time before that data is actually available. With respect to the NEW DAY study, it is a 18-month end point. And so, the hope is we have completed enrollment by the end of the first quarter, and then we would still have data in 2024.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Rick Eiswirth for closing remarks.

Rick Eiswirth: Thank you. I want to thank everybody for participating on today’s call and your continued interest in Alimera, and we look forward to sharing our ongoing progress when we report our fourth quarter and full year 2022 results early next year. Thank you and have a great day.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect